🧠 Early-Stage Alzheimer's Treatment Window Simulator

Placeholder title: the MCI-to-dementia continuum

Placeholder lead sentence on the Alzheimer's disease stage spectrum.

• ~15%: MCI prevalence (Placeholder cohort note)
• ~10-15%/yr: Conversion rate (Placeholder progression note)
• Placeholder: Mild dementia onset (Placeholder marker)
• Placeholder: Moderate dementia (Placeholder marker)

Placeholder section heading: defining the spectrum

Placeholder paragraph describing the disease stage spectrum.

Placeholder key insight about the disease spectrum.

Placeholder title: treatment efficacy declines with stage

Placeholder lead sentence on efficacy differences across stages.

• Placeholder: MCI response (Placeholder note)
• Placeholder: Mild dementia response (Placeholder note)
• Placeholder: Moderate dementia response (Placeholder note)
• Placeholder: Trial endpoint (Placeholder note)

Placeholder section heading: efficacy by stage

Placeholder paragraph describing efficacy differences by stage.

Placeholder key insight about efficacy decline.

Placeholder title: the therapeutic window narrows

Placeholder lead sentence on the narrowing treatment window.

• Placeholder: Window open (Placeholder note)
• Placeholder: Window narrowing (Placeholder note)
• Placeholder: Window closed (Placeholder note)
• Placeholder: Key driver (Placeholder note)

Placeholder section heading: why the window narrows

Placeholder paragraph describing why the window narrows with progression.

Placeholder key insight about window narrowing.

Placeholder title: early diagnosis enables early treatment

Placeholder lead sentence on early diagnosis pathways.

• Placeholder: Biomarker lead time (Placeholder note)
• Placeholder: Diagnostic delay today (Placeholder note)
• Placeholder: PET/CSF biomarkers (Placeholder note)
• Placeholder: Blood biomarkers (Placeholder note)

Placeholder section heading: diagnostic pathways

Placeholder paragraph describing early diagnosis pathways.

Placeholder key insight about early diagnosis benefit.

Placeholder title: stage-based eligibility criteria

Placeholder lead sentence on eligibility criteria for treatment.

• Placeholder: Label restriction (Placeholder note)
• Placeholder: Amyloid PET required (Placeholder note)
• Placeholder: ARIA monitoring (Placeholder note)
• Placeholder: APOE4 consideration (Placeholder note)

Placeholder section heading: eligibility criteria

Placeholder paragraph describing stage-based eligibility criteria.

Placeholder key insight about eligibility limits.